What Analysts Have to Say About Flexion Therapeutics (FLXN)?

If Exact Sciences Corporation (NASDAQ:EXAS) shares can stay above the price resistance around $48.8 a share, that could help propel Exact Sciences Corporation (NASDAQ:EXAS) higher to the next line of resistance at $49.53 a share. The typical day in the last two weeks has seen about a 12.46% volatility. Needham & Company LLC reissued a "buy" rating and issued a $36.00 price objective (up previously from $34.00) on shares of Flexion Therapeutics in a research report on Thursday, August 10th. Increasing profits are the best indication that a company can pay dividends and that the share price will trend upward. Flexion Therapeutics, Inc.is given 4 buy-equivalent recommendations, 0 sells and 0 holds.

The price target set for the stock is $81.03 and this sets up an interesting set of potential movement for the stock, according to data from Finviz's Research.

Flexion Therapeutics (NASDAQ FLXN) traded up 2.14% during mid-day trading on Tuesday, hitting $26.77. The stock's 50 day moving average is $25.08 and its 200 day moving average is $22.65.

Important Factors to Analyse A Good Investment: Kinder Morgan, Inc. (NYSE: KMI)
Following the completion of the purchase, the director now owns 14,587 shares in the company, valued at approximately $295,240.88. Whittier Of Nevada holds 0% of its portfolio in Exelon Corporation (NYSE:EXC) for 1,242 shares. 267,561 are held by Blackrock.

Wall Street analysts are predicting that Flexion Therapeutics (NASDAQ:FLXN) will report earnings per share of $-0.95 in their quarterly report. Previously Flexion Therapeutics (NASDAQ:FLXN) reported $-0.91 earnings per share (EPS) for the quarter, missing the consensus estimate of $-0.82 by $-0.09 with surprise factor of -11%.

Flexion Therapeutics, Inc. was covered by a number of analysts recently, 4 rated the stock as Buy, 4 rated Outperform, 0 rated Hold, 0 gave an Underperform and 0 rated sell. Flexion Therapeutics, Inc.is headquartered in Burlington, Massachusetts. Finally, BMO Capital Markets reissued a "buy" rating on shares of Flexion Therapeutics in a research report on Friday, August 11th. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of U.S. & worldwide copyright laws. Relative Strength Index (RSI-14) for Flexion Therapeutics, Inc. The shares were purchased at an average price of $24.15 per share, for a total transaction of $72,450.00. Outstanding shares refer to a company's stock presently held by all its shareholders, counting share blocks held by institutional shareholders and restricted shares owned by the company's officers and insiders. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. During the past three months the stock gain 9.67%, bringing six months performance to 0.23%.

Let's take a look at how the stock has been performing recently. The company's institutional ownership is monitored at 0 percent. Insider ownership during the a year ago has decreased by a net of 12845 shares. Advisor Group Inc. increased its holdings in Flexion Therapeutics by 205.9% during the second quarter. Wasatch Advisors Inc. now owns 1,018,219 shares of the specialty pharmaceutical company's stock worth $20,588,000 after buying an additional 376,745 shares during the period. (FLXN) to generate earnings per share of $3.80 in 2017. Finally, Swiss National Bank lifted its holdings in Flexion Therapeutics by 13.2% in the 1st quarter. The Manufacturers Life Insurance Company now owns 21,802 shares of the specialty pharmaceutical company's stock worth $441,000 after buying an additional 811 shares during the period. The original version of this story can be viewed at https://www.dispatchtribunal.com/2017/10/12/laidlaw-reiterates-buy-rating-for-flexion-therapeutics-inc-flxn.html. The Company is focused on the development and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis and post-operative pain. The Company's lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Latest News